ASCO 2025 | Future directions in integrating radiomics into clinical practice

Lukas Delasos • 2 Jun 2025

ASCO 2025

General

Lukas Delasos, DO, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses the emerging role of radiomics in clinical trial development and potential translation into clinical practice. By utilizing imaging data to predict a patient’s response to treatment, radiomics possess the capability for subsequently personalizing treatment routes. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.